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Objectives To identify which treatments are most clinically effective for the relief of VMSs for women in natural menopause without hysterectomy.
Search strategy English publications in MEDLINE, Embase, and The Cochrane Library up to 13 January 2015 were searched.
Selection criteria Randomised controlled trials (RCTs) of treatments for women with a uterus for the outcomes of frequency of VMSs (up to 26 weeks), vaginal bleeding, and discontinuation.
Data collection and analysis Bayesian network meta-analysis (NMA) using mean ratios (MRs) and odd ratios (ORs).
Main results Across the three networks, 47 RCTs of 16 treatment classes (n = 8326 women) were included. When compared with placebo, transdermal estradiol and progestogen (O+P) had the highest probability of being the most effective treatment for VMS relief (69.8%; MR 0.23; 95% credible interval, 95% CrI 0.09-0.57), whereas oral O+P was ranked lower than transdermal O+P, although oral and transdermal O+P were no different for this outcome (MR 2.23; 95% CrI 0.7-7.1). Isoflavones and black cohosh were more effective than placebo, although not significantly better than O+P. Not only were selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs) found to be ineffective in relieving VMSs, but they also had significantly higher odds of discontinuation than placebo. Limited data were available for bleeding, therefore no conclusions could be made.
Introduction
Menopausal symptoms are extremely common. Vasomotor symptoms (VMSs) comprising hot flushes and night sweats are the most common menopausal symptoms, occurring in approximately 75% of postmenopausal women in the UK, with 25% of these being severely affected. 1 The duration and severity of menopausal symptoms experienced are not uniform: symptoms may develop in the years before the final menstrual period and may persist for a few years or for many years in postmenopause.
Hot flushes often begin as the sudden sensation of heat centred on the upper chest and face. In some instances, this will become generalised, lasting for several minutes, and can be associated with profuse perspiration, palpitations or anxiety, which may be very distressing and limit activities of daily living, particularly when they occur repeatedly during the day and at night. At night, hot flushes and night sweats will often cause insomnia that leads to fatigue. The mechanism of VMSs appears to involve the central nervous system, possibly linked to a narrowing of the thermoregulatory neutral zone in women with hot flushes, and is associated with instability of the skin blood vessels. 2 Different treatment options, both pharmacological and non-pharmacological, have been used by women to relieve VMSs during menopause. Some of these treatments, such as hormone replacement therapy (HRT) target a 'replacement' of estrogen levels. HRT comprises synthetic hormones including estradiol, conjugated equine estrogens, estradiol valerate and several synthetic progestogens, as well as tibolone, which exhibits estrogenic, progestogenic, and androgenic effects. Other treatments, such as herbal medicines and psychological therapies, may work in different ways. As VMSs may resolve naturally, some women simply do not wish to take hormones, whereas for others HRT is contraindicated: for example, women who have (or are at high risk of) hormone-dependent cancer.
We aim to present the evidence obtained via a systematic review (SR), using network meta-analysis (NMA), of pharmacological and non-pharmacological treatments for the relief of VMSs, relief of adverse events (such as vaginal bleeding), and discontinuation. This NMA formed part of the evidence that underpinned the development of the National Institute of Health and Care Excellence (NICE) guideline on menopause (NG23; www.nice.org.uk/guida nce/ng23). 3 The use of NMA is recommended in healthcare decision-making when multiple treatments are considered for one indication and these treatments have not been directly compared in the same trials.
Methods

Systematic reviews
The protocol of the SR was agreed by the Guideline Development Group (GDG) (Appendix S1), was conducted as part of the development of the NICE guideline on menopause (NG23; www.nice.org.uk/guidance/ng23), and is reported according to the preferred reporting items for systematic reviews and meta-analyses (PRISMA) extension statement for systematic reviews incorporating NMAs of healthcare interventions. 4 A cost-effectiveness model using results from this NMA, in addition to other evidence, was used by the GDG to make recommendations in the guideline. In summary, the SRs included only randomised controlled trials (RCTs) that assessed pharmacological and/or non-pharmacological treatments for reducing the frequency of VMSs, treatment discontinuation, and vaginal bleeding for women aged 45 years or older with a diagnosis of natural menopause (defined as amenorrhea for at least 12 consecutive months).
The population in the NMA protocol was stratified into three groups that formed three networks of connected treatments: women with a uterus; women without a uterus; and women with a history or at risk of breast cancer. This paper presents the results of the first network (women with a uterus). For non-estrogenic treatments we included studies of women without a uterus, as their effect was found to be clinically similar. For studies investigating estrogen plus progestogen we included mixed studies of women with a uterus and without a uterus, as long as more than twothirds (66.6%) of the study sample were women with a uterus (Appendix S1).
The efficacy end point was the frequency of VMSs at the end of treatment, whereas vaginal bleeding and treatment discontinuation were considered measures of adverse events. Although the distress caused by VMSs may have been an equal relevant outcome for women in menopause, the frequency of VMSs was the most commonly reported outcome in studies, and the Guideline Committee highlighted that VMSs were highly prevalent among women seeking treatment for menopausal symptoms. Vaginal bleeding and treatment discontinuation were prioritised because of their importance on the continuity of health care, costs of further treatment, and long-term impact.
The time points of outcomes recorded were guided by clinical decision on the minimum duration of a trial for the intervention to be effective. Non-hormonal treatments were considered by the GDG to take a minimum of 4 weeks to be effective, whereas hormonal treatments were considered to take longer (12 weeks). As shorter-term outcomes were the focus of this review, 26 weeks was considered to be the maximum follow-up time that we would include, to avoid any long-term changes in treatment efficacy that might cause heterogeneity within the network.
All searches were conducted in MEDLINE, Embase, and The Cochrane Library up to 13 January 2015, and were restricted to articles written in English according to the parameters stipulated within the NICE Guidelines Manual 2015 (www.nice.org.uk/article/PMG20/chapter/4-Develop ing-review-questions-and-planning-the-evidence-review; Appendix S2). Literature reviews, posters, letters, editorials, comment articles, unpublished studies, and studies not in English were excluded. Full search strategies were published as part of the full NICE guideline (www.nice.org.uk/guida nce/ng23/evidence/appendices-ag-559549262).
Search strategies were quality assured by cross-checking reference lists of highly relevant papers and comparing with search strategies in other SRs.
Data extraction
Data were double extracted in a structured form, using a guide developed by the authors for Data Extraction for Complex Meta-anALysis (DECiMAL), independently by two reviewers. 5 Discrepancies in data extraction were addressed by a senior reviewer who resolved any conflicts.
The quality of the studies was evaluated using two domains (risk of bias, indirectness) of the 'Grading of Recommendations Assessment, Development and Evaluation (GRADE) toolbox' developed by the international GRADE working group (www.gradeworkinggroup.org). 6 Detailed results for risk of bias domains are shown in Table S2 .
Statistical models
The NMA was formulated to synthesise direct and indirect evidence of the effects of treatments to reduce the frequency of VMSs, treatment discontinuation, and vaginal bleeding using the software WINBUGS 1.4.3. We used statistical models for both fixed and random effects that allowed the inclusion of multi-arm trials and accounted for the correlation between arms in the trials with any number of trial arms.
7 A class effect model was selected for the NMA with the underlying assumption that the effectiveness of different treatments under the same class would be comparable. This decision was made to maximise the availability of data and borrow strength from different trials. Data were available on dosing for many treatments, but the sparseness of the networks meant that it was necessary to borrow strength on dosing within treatments by assuming different doses of the same treatment had the same class effects (fixed-effects model). A model allowing for within-class variability was also assessed to check whether it improved the model fit and reduced heterogeneity (random-effects model). Two random effects models for this were explored: an exchangeable dose effects model, where the pooled relative effects of different treatment doses were assumed to be randomly distributed within each treatment with a common variance (requiring modelling using a second variance parameter); and a fixed dose effects model, where the pooled relative dose effects are assumed equal for all doses of a treatment. For treatments where dosing information was not available, the relative effect at the dose level was assumed to be equal to the treatment effect in both models.
WINBUGS code was adapted from Dias et al. (2011), and is available from the NICE appendices (http://www.nice.org. uk/guidance/ng23/evidence/appendices-ik-559549264). The following prior distributions were used: log mean ratios (MRs) in the comparator arms for each study were normally distributed with a mean of zero and a variance of 1000; pooled log MRs at the treatment or class level (depending on the model used) were normally distributed with a mean of zero and a variance of 1000; between-study standard deviation followed a uniform distribution between zero and two; within-class standard deviation followed a uniform distribution between zero and two;
Placebo was selected as the baseline comparator for all networks as it was the treatment arm most commonly evaluated in RCTs. As no dependency on time was identified in exploratory analyses, discontinuation of treatment and vaginal bleeding were treated as dichotomous outcomes, and were modelled on the log-odds ratio scale ( Figure S2 ). Exploratory analyses also showed that the baseline frequency of VMSs followed an overdispersed Poisson distribution, and thus it was not appropriate to use a standard Poisson distribution to model the frequency of VMSs ( Figure S3 ). The negative binomial distribution can be used to model an overdispersed Poisson distribution by including a parameter that accounts for the overdispersion. [8] [9] [10] The mean of this negative binomial is interpreted as the rate of the overdispersed Poisson distribution, and can be approximated by a normal distribution. We therefore model the mean using a log-link function, and relative treatment effects are estimated as log-mean ratios. Our motivation was to model data as closely as possible to the mechanism by which they were generated (i.e. from an overdispersed Poisson distribution), and this approximation provided a simple computational solution whilst retaining the interpretation of the pooled effect as mean rates of VMSs.
On the log mean ratio scale, the final and change from baseline frequencies of VMSs could not be pooled, so the change from baseline frequency was transformed so that all effects could be modelled as final frequencies. A correlation coefficient of 0.55 was used to estimate the final frequencies from the change from baseline frequency. This was calculated from two included studies that reported baseline, final, and change from baseline results in full. 11, 12 All three models (fixed effects, random effects with fixed dose effects, and random effects with exchangeable dose effects) were compared based on residual deviance and deviance information criteria (DIC). 7, 13 Between-studies heterogeneity estimates from random effects models are presented as median and 95% credible intervals (95% CrIs).
Inconsistency in the networks was tested in closed loops of treatment comparisons by node-splitting.
14 This technique allows the splitting of direct and indirect information contributing to each treatment effect. The difference between these contributions can be statistically tested, with a rejection of the null hypothesis indicating significant inconsistency in the network.
The output of the NMA was expressed as the probability of each treatment being the best for an outcome (based on the proportion of Markov-chain simulations in which a treatment ranked first) and the ranking of treatments (presented as median rank and its 95% CrI). The estimation of summary estimates (MRs or odds ratios, ORs) were also calculated for comparisons of the direct and indirect evidence using medians and 95% CrIs from the posterior distributions.
Two types of sensitivity analyses were predefined in the NMA protocol. The first focused on changing the value of the correlation coefficient used to estimate final frequencies of VMSs from change from baseline, from 0.55 in the original analysis to a typically assumed correlation between baseline and follow-up of 0.75. The second analysis tested whether differences in treatment efficacy could be explained by differences in dosing. Studies investigating the treatment of low-dose oral estradiol plus progestogen were removed from the analysis to determine whether this dose was reducing the overall efficacy of oral estradiol plus progestogen in the model. The final results were not found to be sensitive to either of these changes.
A further post-hoc sensitivity analysis was considered to investigate the effect of including mixed population studies (women with and without a uterus) of estrogen plus progestogen; however, as there was only a single study that included mixed populations for this treatment comparison, 15 the exclusion of the study removed estrogen plus progestogen oral from the network and prevented an estimation of the efficacy of this treatment. No other results were affected by the exclusion of this study.
Results
A total of 47 RCTs matched the protocol, 11, 12, presented information for at least one of the outcomes, and were included in the NMA ( Figure S1 ). For the first two networks (frequency of VMSs and discontinuation of treatment), DIC suggested that there was a small difference between any of the models (differences of <5 points are not considered meaningful; Table S7 ). The residual deviance for the random effects model with fixed-dose effects for both these networks was slightly closer to the number of unconstrained data points than either of the other models, however (for the fixed effects and random effects with exchangeable dose effects, respectively). Therefore, the results of the random effects model with fixed dose effects are presented for these two networks. For the network of vaginal bleeding, the results of the fixed effects model are presented, as the estimate of heterogeneity for the random effects model was unstable and strongly influenced by the prior distribution.
Reducing the frequency of VMSs
A total of 32 RCTs of 12 treatment classes (placebo, sham acupuncture, estrogen plus progestogen non-oral, estrogen plus progestogen oral, tibolone, raloxifene, selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs), isoflavones, Chinese herbal medicine, black cohosh, multibotanicals, and acupuncture) with a sample size of 4165 women were included for the NMA for VMSs (Figure 1 ; Table S1 ). Two included RCTs were at very high risk of bias, and 13 were at high risk (Table S2 ). The other 21 RCTs were at low or moderate risk of bias. The combination of estrogen plus progestogen administered via patches was found to be better than placebo (MR 0.23; 95% CrI 0.09-0.57) at relieving VMSs for women in menopause, and had the highest probability of being the best treatment (68.9%; Figure 2A ; Table 1 ). Although the 95% CrI for the combination of oral estrogen plus progesterone compared with placebo was wide (MR 0.52; 95% CrI 0.25-1.06), the point estimate suggested that it may have good efficacy, similar to that of transdermal estrogen plus progestogen. In addition, there was strong evidence to suggest that the combination of estrogen plus progestogen via patches was more effective than raloxifene, SSRIs/SNRIs, isoflavones, and Chinese herbal medicine in relieving VMSs. Isoflavones and black cohosh were also found to be better than placebo. There was no strong evidence of any other effects among other interventions in the network (Table S3) .
High heterogeneity was found between studies, thereby reducing the precision of the estimates. This is likely to have arisen because of the clinical differences in patients included in the studies: the baseline frequency of hot flushes varied considerably between studies. Inconsistency was assessed in the closed loop between placebo, sham acupuncture, and acupuncture, but no difference was found between the results obtained through direct and indirect evidence (Table S3) .
Treatment discontinuation
A total of 21 RCTs of ten treatment classes (placebo, estrogen plus progestogen oral, conjugated estrogens plus bazedoxifene, tibolone, SSRIs/SNRIs, gabapentin, isoflavones, Chinese herbal medicine, multibotanicals, and valerian root) with a sample size of 4829 women were included in the network for discontinuation of treatment ( Figure 1 ; Table S1 ). Because of high heterogeneity between the studies included in the NMA, the uncertainty of the results was increased. Inconsistency could not be assessed in this network as there were no closed treatment loops. Only four RCTs were at a high risk of bias. The other 17 were at a low or moderate risk of bias (Table S2 ). There was evidence that the combination of non-oral estrogen plus progestogen had significantly lower odds of discontinuation than than placebo (OR 0.61; 95% CrI 0.37-0.99). In addition, there was evidence that conjugated estrogens plus bazedoxifene (OR 0.31; 95% CrI 0.1-1.00) was more effective than placebo in this outcome, although there was considerable uncertainty in this result. There was strong evidence that SSRIs/SSNIs were worse than placebo (OR 1.66; 95% CrI 1.07-2.61) on discontinuation of treatment. There was evidence that tibolone and SSRIs/SNRIs were worse than non-oral estrogen plus progestogen and conjugated estrogens plus bazedoxifene for this outcome ( Figure 2B ; Tables 2 and S4) .
In this analysis, conjugated estrogens plus bazedoxifene and valerian root were found to have the highest probability (37.3 and 37.0%, respectively) of being the best treatments in relation to the discontinuation of treatment among interventions up to 26 weeks, although noted that these probabilities are small and below 50%.
Vaginal bleeding
The network of vaginal bleeding included five RCTs of five treatment classes (placebo, estrogen plus progestogen oral, tibolone, SSRIs/SNRIs, and gabapentin; Figure 1 ; Table S1 ), with a sample size of 1367 women. Neither heterogeneity nor inconsistency could be assessed in the network because of its sparseness. A fixed effects model was used and there were no closed treatment loops. One study was at high risk of bias, one was at low risk of bias, and the other three were at moderate risk of bias (Table S2 ). The sparseness of data within the network meant that there was a high degree of uncertainty in estimates, and no conclusions could be drawn regarding the effects of treatments on vaginal bleeding (adverse event; Figure 2C ; Table S5 and S6).
Discussion
This paper summarizes the evidence included in three SRs and analysed in NMAs for the outcomes of relief of frequency of VMSs, treatment discontinuation, and vaginal bleeding among pharmacological and non-pharmacological treatments for women with a uterus who have undergone a natural menopause. To our knowledge, this is the first publication using this type of complex analysis in the research field of menopause.
VMS -Women with a uterus
Discontinuation -Women with a uterus
Vaginal bleeding -Women with a uterus A C B Figure 1 . Network plots for the three NMAs, VMS (A), discontinuation due to adverse events (B) and vaginal bleeding (C). The size of the nodes is proportional to the number of women in the NMA who received a particular treatment. The thickness of the lines is proportional to the number of studies that make a particular comparison included in the NMA. Treatments not connected to a networks could not be included in that NMA.
Main findings
The NMA results showed that for women with a uterus, the estrogen plus progestogen transdermal patch was the most effective treatment to relieve the frequency of VMSs, with a lower odds of discontinuation compared with all the other available treatments (hormonal, non-hormonal, and non-pharmacological). There was evidence that estrogen plus progestogen taken orally may be more effective to relieve VMSs than placebo, but this did not rank as highly as transdermal estrogen plus progestogen in the hierarchy of the best treatment options for this outcome. Both may be considered as options in the clinical setting, however, depending on the individual's response to treatment.
Although isoflavones and black cohosh were also shown to be more effective than placebo in the relief of VMSs for women with a uterus, there was no evidence that their efficacy differed from combined estrogen plus progestogen. These results should be interpreted with caution, however, as there was a variety of herbal preparations used in different studies. SSRIs/SNRIs were not found to be effective in relieving VMSs, but were found to have higher odds of discontinuation compared with the other treatments, as would be expected with the serious side-effects profile of these treatments. The NMA demonstrated that women treated with non-oral estradiol plus progestogen or with conjugated estrogens plus bazedoxifene were less likely to discontinue treatment than if they were treated with placebo or tibolone, however.
No conclusive points could be made for the outcome of vaginal bleeding for women with a uterus given the limited data for this outcome and the lack of inclusion of several interventions in the network.
During the NICE guideline development, results of clinical efficacy from the NMA were incorporated into a probabilistic cost-effectiveness analysis that informed the decisionmaking of the Guideline Committee. The committee concluded that women with a uterus should be offered the treatment of estrogen and progestogen (HRT) for the relief of VMSs, following an individualised approach, and after discussion of the short-term (up to 5 years) and longer-term benefits and risks. Health professionals should not routinely offer SSRIs, SNRIs, or clonidine as a first-line treatment for VMSs alone, and should explain to women that although there is some evidence that isoflavones or black cohosh may relieve VMSs, there are health concerns in relation to safety of multiple preparations and interactions with other medicines (http://www.nice.org.uk/guidance/ng23).
Strengths and limitations
This is the first NMA designed to include the simultaneous comparison of randomised evidence aiming to reduce the frequency of VMSs for women in menopause. Advanced Table 1 . Log mean ratios (with 95% CrIs) of all interventions in the network and the probability of being the best treatment for reducing the frequency of VMSs Between-study heterogeneity: standard deviation on the log MRs scale (SD) (95% CrI) 0.50 (0.37, 0.70). statistical techniques were employed to make best use of the available evidence. A novel NMA model that accounts for the nature of the VMS data, distributed as an overdispersed Poisson distribution, and incorporates class effects and transformation of change from baseline scores of outcomes, was developed to make use of as many relevant and available data as possible. We were therefore simultaneously able to compare several interventions of interest to women and policymakers that had not been compared previously in head-to-head trials. Overall there were relatively few studies included in the networks compared with the number of treatment comparisons. This may have led to the within-class standard deviation parameter not being fully informed, which could explain the better fit of the fixed dose effect random effects model, compared with the exchangeable dose effect random effects model. A dose-response relationship might have been expected in the data, but as the protocol specified that treatments had to be administered within selective doses specified in the British National Formulary, the range of doses was often very small. Furthermore, body weights and absorption can vary substantially between patients, and this is likely to lead to as much (if not more) variation in the bioavailability of treatment than the dose administered.
Several decisions were made at the protocol stage that affected the selection of data included in the networks, and therefore the representativeness of all available evidence in this area. For example, we included only studies published in English, which may have limited our evidence on some treatments (e.g. Chinese herbal medicines), and publication bias was not easily assessed. Furthermore, it was decided to examine the role of different treatments used to reduce the frequency rather than the severity of VMSs, which resulted in some treatments such as cognitive behaviour therapy being excluded from the NMA. The selection of outcomes for inclusion in the NMA was based on both their clinical importance and relevance to women in menopause. Frequency of VMSs, discontinuation, and vaginal bleeding were prioritised for inclusion because of their high prevalence and the availability of evidence.
Assumptions were also made for the minimum duration of trials for inclusion in the NMA and the minimum acceptable criteria for mixed population studies. These assumptions are commonly made when a complex meta-analysis is designed, and aim to increase the homogeneity and validity of the included data; however, this resulted in a number of studies being excluded from further analysis. Some studies were also excluded because the data reported did not give an indication of variability (no information on standard deviation or standard error of results). For the small minority of studies that were excluded because they did not connect to the network, their results and whether they would influence decision-making were further discussed with the GDG. This information was used as supplementary evidence to facilitate the group's discussion, which recognised the importance of these treatments in the management of some women with menopause, especially if they do not wish to be treated with pharmacological treatments (such as HRT), and these options were highlighted in terms of the provision of general advice and information.
Interpretation
This is the first NMA designed to include the simultaneous comparison of randomised evidence from pharmacological and non-pharmacological treatments aiming to reduce the frequency of VMSs for women in menopause. After taking into account the assumptions used for this NMA and the limitations of this approach, these results provided a comprehensive framework for decision-making by combing direct and indirect evidence on treatments for the relief of VMSs in menopause. Our reviewed literature did not identify any other similar type of analysis that could be used for our results comparison.
Conclusion
There is evidence that transdermal estradiol plus progestogen greatly reduces the frequency of hot flushes in women with a uterus. Although there is some evidence of the efficacy of oral estrogen plus progestogen treatment, the health economic analysis and the expert opinion of the GDG supported the administration of both types of estradiol plus progestogen in clinical practice.
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